Hossein Borghaei

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Bogdan Żurawski et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

Medicine, Oncology, Pharmacology +13

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi et al. · Cancer Cell · 2018 · 1.2K citations · Full text

Medicine, Immunology, Oncology +17